Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: ACBT vs CCPT Quality of life · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy FEV1: % predicted (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy FVC: % predicted (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Sputum weight (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Number of pulmonary exacerbations · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs OD Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Personal preference · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs OD Number of pulmonary exacerbations · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs other breathing techniques Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs other breathing techniques Number of pulmonary exacerbations · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs exercise Personal preference · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs exercise Sputum weight (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Sputum weight (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Personal preference · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anti‐VEGF vs no anti‐VEGF Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma Anti‐vascular endothelial growth factor for neovascular glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Hypertension (grade ≥ 2) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Any adverse events (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Hypertension (grade ≥ 2) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula/perforation (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab vs chemotherapy alone Quality of life · recurrent platinum‐resistant EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI vs chemotherapy alone Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone Any adverse events (grade ≥3)Â · recurrent EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone Hypertension (grade ≥ 2)Â · recurrent EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by maintenance bevacizumab vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs assessment and feedback Extent of substance use post‐intervention · people with substance use (adults, young adults, adolescents) Motivational interviewing for substance use reduction (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs assessment and feedback Readiness to change · people with substance use (adults, young adults, adolescents) Motivational interviewing for substance use reduction (2023) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs assessment and feedback Retention in treatment · people with substance use (adults, young adults, adolescents) Motivational interviewing for substance use reduction (2023) · Cochrane | no estimate extracted | NR | No studies |
Health education vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Engagement of community leaders vs routine care Proportion of children under 5 years of age fully immunised with all scheduled vaccines · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Engagement of community leaders vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Engagement of community leaders vs routine care Cost of the intervention · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Engagement of community leaders vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Health education vs routine care Cost of the intervention ‐ reported narratively in 2 studies · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Health education vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Monetary incentives vs routine care Proportion of children who received DTP3 or Penta 3 by 1 year of age · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Monetary incentives vs routine care Proportion of children who received all recommended vaccines by 2 years of age · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Health education vs routine care Proportion of children who received all recommended vaccines by 2 years of age · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Monetary incentives vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Monetary incentives vs routine care Cost of the intervention · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Monetary incentives vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home‐based record combined with other interventions vs routine care Proportion of children who received all recommended vaccines by 2 years of age · children aged 1 year Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home‐based record combined with other interventions vs routine care Proportion of children who received the vaccine under study · children aged 1 year Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home‐based record combined with other interventions vs routine care Proportion of children under 5 years of age fully immunised with all scheduled vaccines · children aged 1 year Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |